Exploration of biomarkers for early recognition of FVIII inhibitor development in previously untreated severe hemophilia A patients: Hemophilia Inhibitor PUP Study and beyond

被引：0
|
作者：
Hofbauer, C. J. [1 ]
Male, C. [2 ]
Brown, D. [3 ]
Santagostino, E. [4 ]
Oldenburg, J. [5 ]
Scheiflinger, F. [1 ]
Reipert, B. M. [1 ]
机构：
[1] Baxter BioSci, Vienna, Austria
[2] Med Univ Vienna, Vienna, Austria
[3] Univ Texas Houston, Houston, TX USA
[4] Univ Milan, Milan, Italy
[5] Univ Clin Bonn, Bonn, Germany
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2013年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：133 / 133
页数：1
相关论文
共 50 条
  • [41] RECOMBINANT FVIII (KOGENATE) TREATMENT OF PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH HEMOPHILIA-A - UPDATE OF SAFETY, EFFICACY AND INHIBITOR DEVELOPMENT AFTER 5 STUDY YEARS
    LUSHER, JM
    ARKIN, S
    ABILDGAARD, CF
    HURST, D
    PEDIATRIC RESEARCH, 1995, 37 (04) : A161 - A161
  • [42] Inhibitor incidence in previously untreated patients (PUP) with hemophilia A and B - a 10-year-follow up of the prospective multicenter study.
    Kreuz, W
    Auerswald, GKH
    Budde, U
    Lenk, H
    BLOOD, 2004, 104 (11) : 81B - 81B
  • [43] Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan
    Masashi Taki
    Katsuyuki Fukutake
    Tadashi Matsushita
    Keiji Nogami
    Midori Shima
    Akira Yoshioka
    Junki Takamatsu
    Morio Arai
    Hiroshi Takagi
    Haruhiko Uchikawa
    Werner Engl
    Akira Shirahata
    International Journal of Hematology, 2019, 109 : 70 - 78
  • [44] Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan
    Taki, Masashi
    Fukutake, Katsuyuki
    Matsushita, Tadashi
    Nogami, Keiji
    Shima, Midori
    Yoshioka, Akira
    Takamatsu, Junki
    Arai, Morio
    Takagi, Hiroshi
    Uchikawa, Haruhiko
    Engl, Werner
    Shirahata, Akira
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (01) : 70 - 78
  • [45] Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study
    Gouw, Samantha C.
    van der Bom, Johanna G.
    van den Berg, H. Marijke
    BLOOD, 2007, 109 (11) : 4648 - 4654
  • [46] Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates
    von Auer, CH
    Oldenburg, J
    von Depka, M
    Escuriola-Ettinghausen, C
    Kurnik, K
    Lenk, H
    Scharrer, I
    AUTOIMMUNE DISEASES AND TREATMENT: ORGAN-SPECIFIC AND SYSTEMIC DISORDERS, 2005, 1051 : 498 - 505
  • [47] Low inhibitor incidence in previously untreated hemophilia A patients (PUPs) treated with Octanate®
    Klukowska, A.
    Laguna, P.
    Komrska, V.
    Jansen, M.
    HAEMOPHILIA, 2010, 16 : 37 - 37
  • [48] The hemophilia inhibitor PUP study (HIPS) - design and methods
    Brown, D.
    Reipert, B.
    Santagostino, E.
    HAEMOPHILIA, 2010, 16 : 30 - 30
  • [49] Inhibitor development in hemophilia patients
    Ören, H
    Yaprak, I
    Deveci, C
    Irken, G
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 136 - 136
  • [50] RECOMBINANT-FVIII (KOGENATE) TREATMENT OF PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH HEMOPHILIA-A - UPDATE OF SAFETY, EFFICACY, AND INHIBITOR DEVELOPMENT AFTER 5 STUDY YEARS
    LUSHER, J
    ARKIN, S
    ABILDGAARD, CF
    HURST, D
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1012 - 1012
12345